Trial intelligence / Profile preview

RESONAR study of rituximab in active rheumatoid arthritis refractory to anti-TNF therapy

2008-002381-55Phase 4Terminated

Sponsor
Roche
Start
Aug 2008
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 4, double-blind trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Mean change in RAMRIS score at 6 months. Started Aug 2008; status: terminated.

02

Drugs

rituximab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2008-002381-55.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-002381-55.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call